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Abstract 
Background: Endometrial regenerative cells (ERCs) is an attractive novel type of adult mesenchymal stem cells that 
can be non-invasively obtained from menstrual blood and are easily replicated at a large scale without tumorigenesis. 
We have previously reported that ERCs exhibit unique immunoregulatory properties in experimental studies in vitro 
and in vivo. In this study, the protective effects of ERCs on renal ischemia–reperfusion injury (IRI) were examined.
Methods: Renal IRI in C57BL/6 mice was induced by clipping bilateral renal pedicles for 30 min, followed by reperfu-
sion for 48 h. ERCs were isolated from healthy female menstrual blood, and were injected (1 million/mouse, i.v.) into 
mice 2 h prior to IRI induction. Renal function, pathological and immunohistological changes, cell populations and 
cytokine profiles were evaluated after 48 h of renal reperfusion.
Results: Here, we showed that as compared to untreated controls, administration of ERCs effectively prevented 
renal damage after IRI, indicated by better renal function and less pathological changes, which were associated with 
increased serum levels of IL-4, but decreased levels of TNF-α, IFN-γ and IL-6. Also, ERC-treated mice displayed signifi-
cantly less splenic and renal CD4+ and CD8+ T cell populations, while the percentage of splenic CD4+CD25+ regula-
tory T cells and infiltrating M2 macrophages in the kidneys were significantly increased in ERC-treated mice.
Conclusions: This study demonstrates that the novel anti-inflammatory and immunoregulatory effects of ERCs are 
associated with attenuation of renal IRI, suggesting that the unique features of ERCs may make them a promising 
candidate for cell therapies in the treatment of ischemic acute kidney injury in patients.
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Background
Renal ischemia–reperfusion injury (IRI) is a major cause 
of clinical acute kidney injury (AKI), which is a frequent 
and serious problem in transplantation, renal surgery, 
renal diseases and trauma [1]. Vigorous research on 
IRI has been conducted, but the mortality rate of AKI 
remains high. There is no effective therapy available to 
treat renal IRI or ischemic AKI. Thus, new therapeutic 
approaches are desperately needed.
The underlying mechanisms of renal IRI are complex 
and multiple factors are involved. The pathophysiology 
of renal IRI includes initial cellular damage caused by 
ischemia, as well as delayed renal injury resulting from 
inflammatory and immune responses following reperfu-
sion [2]. Numerous studies have demonstrated that renal 
IRI is an inflammatory disease, which is mediated by 
innate and adoptive immune responses [3–6]. The acti-
vation and infiltration of neutrophils [5, 7], macrophages 
[8], T lymphocytes [9], monocytes and inflammatory 
mediators are involved in modulating severity of injury in 
experimental models of renal IRI [10–13]. Animal models 
have showed that inflammation begins as early as 30 min 
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activated by renal IRI dramatically improves renal func-
tion and histological integrity after ischemia [14].
In the past few years, stem cell-based therapy as a 
promising alternative solution draws considerable atten-
tion for disease treatment. As a potential candidate for 
regenerative medicine, mesenchymal stem cells (MSCs) 
promote tissue repair [15–17]. In the meantime, MSCs 
have immunomodulatory, anti-inflammatory properties 
and are immune privileged [18]. These cells can modulate 
the function of immune cells by both cell-to-cell interac-
tion and soluble factor secretion [19, 20]. MSCs can be 
obtained from different tissues including bone marrow 
and adipose tissue. However, the disadvantages of using 
these sources, such as the requirement of invasive access 
method and the cause of related complications, limited 
their clinical use and so on [21, 22].
In 2007, Meng et al. discovered the endometrial regen-
erative cells (ERCs), a novel type of adult MSCs, which 
satisfy the traits of MSCs but overcome the disadvan-
tages of other conventional sources and the fear of kar-
yotypic abnormalities during culture and possibility of 
oncogenesis [22]. We and others have reported that ERCs 
effectively prevent critical limb ischemia [21], attenuate 
ulcerative colitis [23], stroke [24] and burn injury [25] in 
mouse models. Also, it has been found that these human 
cells were not rejected in a xenogeneic animal model [21]. 
However, whether ERCs could be feasible to simultane-
ously suppress inflammatory and immune responses, and 
repair the damaged tissue following IRI remains unclear. 
Thus, the aim of this study was to explore the potential 
role of ERC therapy in prevention of renal IRI.
Methods
Preparation of ERCs for in vivo treatment
ERCs were collected from menstrual blood of women 
(20–40  years old) after informed consent was obtained. 
Five milliliters of menstrual blood were collected by urine 
cup-tubing method in an antibiotic containing solution. 
Mononuclear cells were separated by standard Ficoll 
method, and the resultant samples were suspended in 
Dulbecco’s modified Eagle’s medium (DMEM) high glu-
cose supplemented with 10  % fetal bovine serum (FBS), 
and split into two 10 cm dishes. After overnight incuba-
tion, cultured cells revealed marginal adherence to the tis-
sue culture flask. Cells were cultured with media changing 
twice a week. At the completion of 2 week culture, an out-
growth of adherent cells with a fibroblast-like morphology 
was observed [22]. The estimated adherent cell number at 
the start of culture was approximately 1 × 107 [26].
Animals
Eight-week-old male C57BL/6 mice (Aoyide Co., Tian-
jin, China) weighing 20–25  g were housed under 
conventional experimental environment with 12 h light–
dark cycle in the Animal Care Facility of Tianjin General 
Surgery Institute. The mice had a free access to commer-
cial standard mouse diet and water. All experiments were 
conducted in accordance with the protocols approved by 
the Animal Care and Use Committee of Tianjin Medical 
University (China) according to the Chinese Council on 
Animal Care guidelines.
Experimental groups
The experiment was conducted following the protocol 
described previously [27]. In brief, to test the efficacy of 
ERCs in attenuation of kidney IRI, C57BL/6 mice were 
randomly assigned to three groups (n = 6 per group): (1) 
sham control group, mice were operated by opening and 
closing the abdomen, without clipping the renal pedicles; 
(2) untreated IRI group, through a middle abdomen inci-
sion, bilateral renal pedicles were clipped for 30 min, then 
released [27]; and (3) ERC-treated IRI group, 1 × 106 ERCs 
were intravenously injected 2  h before clipping bilateral 
renal pedicles [28]. After reperfusion was confirmed, the 
abdomen was closed in two layers using standard 6-0 
sutures. Mice were maintained by continuous monitor-
ing using a temperature-controlled self-regulated heating 
system after the completion of surgery. To maintain body 
fluid balance, 1 mL of warm saline was administered intra-
peritoneally immediately after operation. The mice were 
sacrificed 48 h after reperfusion for IRI assessment.
Assessment of renal function
Serum levels of both blood urea nitrogen (BUN) and 
creatinine (Cr) were measured when the mice were sac-
rificed 48  h after renal reperfusion using multichannel 
analyzer in the Tianjin Medical University General Hos-
pital (Tianjin, China) for assessing the renal function.
Histological examination
Kidney tissues from each mouse in each group were fixed 
by 10  % buffered formalin, and embedded in paraffin. 
Paraffin sections of kidneys (5  μm) stained with Hema-
toxylin and eosin (H&E) were used for morphology anal-
ysis under light microscopy. A semi-quantitative score of 
tubular damage including cellular necrosis, loss of brush 
border, cast formation, vacuolization, and tubule dilation 
were counted as follows: 0, none; 1, <10 %; 2, 11–25 %; 3, 
26–45 %; 4, 46–75 %; and 5, >76 % [29].
Immunohistochemistry
To quantitate the cell infiltration, sections were stained 
with antibodies (Abcam, http://www.abcam.com/). We 
performed immunohistochemical staining by using 
anti-CD3 and anti-Ly6G antibodies for detecting intra-
renal cellular infiltration of T cells and neutrophils, 
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respectively. The primary antibody was at a dilution 
of 1:100. Negative control sections, only stained with 
secondary antibodies but without primary antibodies, 
were performed to assess the non-specific staining. 
The specimens were stained according to the instruc-
tions of Strept Avidin–Biotin Complex (SABC) kit. 
Stained sections were photographed using an Olym-
pus inverted microscope (Olympus Imaging America, 
Center Valley, PA).
Flow cytometric analysis
Phenotypic analysis of various immune cells was per-
formed using a flow cytometry with staining with anti-
bodies against CD4, CD8, CD25, F4/80 or CD206 
(eBiosciences, http://www.ebioscience.com/), according 
to the manufacturer’s instructions. The percentage of 
each phenotype of immune cells was analyzed with the 
corresponding Flowjo software.
ELISA
The levels of TNF-α, IFN-γ, IL-6 or IL-4 in the serum 
samples taken from mice 48  h after IRI were measured 
using an ELISA Kit (Biolgend, http://www.biolegend.
com/) according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was performed in SPSS version 17.0 
software (SPSS Inc., Chicago, USA) and the experimen-
tal data were presented as mean  ±  standard deriva-
tion (SD). The data obtained from sham control group, 
untreated IRI group and ERC-treated IRI group were 
compared using one-way analysis of variance (ANOVA) 
to study the effects of ERC treatment on the renal func-
tion, histological scores, cell populations and cytokine 
profiles for repeated measurements. The case number 
for each experiment is specified in the corresponding 
figure. p value (p)  <  0.05 was considered statistically 
significant.
Results
ERCs protected renal function in mice with renal IRI
To determine whether the pre-treatment with ERCs 
could attenuate renal IRI, we subjected mice to bilateral 
kidney IRI for 30 min. Then the serum BUN and Cr levels 
were measured after 48 h of induction of IRI. We found 
that BUN (Fig.  1a) and Cr (Fig.  1b) levels were mark-
edly reduced by ERC treatment compared with those of 
untreated mice after IRI (p < 0.05), although the levels of 
BUN and Cr were slightly higher than those of mice in 
sham control group (p < 0.05).
Treatment with ERCs ameliorated renal pathological 
damages induced by IRI
H&E staining was performed to assess the renal patho-
logical changes. Representative kidney sections and the 
renal damage score were shown in Fig.  2. It was found 
that untreated IRI mice displayed severe tubular damage 
48 h after renal IRI, characterized by widespread tubular 
necrosis, loss of brush border, cast formation, tubular 
dilatation, expansion of Bowman’s capsule and interstitial 
Fig. 1 Infused ERCs improves renal function. Serum samples were collected from mice of the sham, IRI-untreated and ERC-treated groups. In 
comparison with untreated IRI group, infused ERCs significantly reduced serum levels of a BUN and b Cr. Bar graphs represent mean ± SD of three 
separate experiments. p values were determined by one-way ANOVA. Data shown are representative of three separate experiments performed 
(*p < 0.05, vs. IRI-untreated group, # p < 0.05, vs. sham group, n = 6)
Page 4 of 13Sun et al. J Transl Med  (2016) 14:28 
edema (Fig.  2a, IRI-untreated). In contrast, the kidneys 
in ERC-treated mice showed normal histology (Fig.  2a, 
ERC-treated) at the same time point, which was indis-
tinguishable from that of sham control mice (Fig.  2a, 
sham). In addition, the histopathological damage scores 
in ERC-treated group were significantly lower than those 
of untreated IRI group (p < 0.05), which were comparable 
to those of sham control group (Fig. 2b).
ERCs suppressed intra‑renal infiltration of neutrophils 
and T cells after renal IRI
As shown in Fig. 3, neutrophil and CD3+ T cell infiltra-
tions were markedly increased in untreated IRI group as 
compared with those of sham control group and ERC-
treated group. It was suggested that administration of 
ERCs suppressed neutrophil and CD3+ T cell infiltration. 
As a result, histological injury of kidney was attenuated. 
Moreover, loss of the brush border, cast formation and 
tubular dilatation in kidneys were also significantly sup-
pressed in ERC-treated mice.
Infused ERCs increased the percentage of CD4+CD25+ T 
cells in the spleen
The underlying mechanisms of renal IRI are com-
plex, including activation and progression of immune 
response. Regulatory T cells (Tregs), playing a critical 
role in suppression of both adaptive and innate immune 
responses, have been shown to attenuate renal IRI [28, 
30]. In this study, we detected and compared splenic Treg 
population in different groups. There was no significant 
difference in the number of Tregs between untreated IRI 
group and sham control group. In contrast, CD4+CD25+ 
Treg population was significantly increased by ERC treat-
ment in mice with renal IRI (p < 0.05, vs. untreated IRI 
group and sham control group), indicating the protective 
role of Tregs in ERC-mediated kidney protection (Fig. 4).
ERCs decreased the percentages of CD4+ and CD8+ T cells 
in the spleen and kidney after renal IRI
To determine the relationship between the changes of T 
cell population and ERC-mediated renal protection, we 
Fig. 2 Treatment with ERCs significantly attenuates pathological damage induced by IRI in kidneys. Mouse kidneys were subjected to bilateral renal 
pedicles clipping for 30 min, then released and followed by 48 h reperfusion. Mice were sacrificed and the kidneys were harvested 48 h after reper-
fusion. a H&E staining was performed to evaluate renal pathological changes. The representative kidney sections of different groups were displayed. 
Magnification 100×. b Quantitative assessment of kidney damage was performed as described in the “Methods” section. Bar graphs represent 
mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are representative of three separate experi-
ments (*p < 0.05, vs. IRI-untreated group, n = 6)
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investigated the infiltration of CD4+ and CD8+ T cells in 
both spleen (Fig. 5a) and kidney (Fig. 5b) by flow cytom-
etry. The percentages of CD4+ and CD8+ T cells were 
significantly decreased in ERC-treated group compared 
with those of untreated IRI group in both spleen and kid-
ney (Fig. 5c, p < 0.01), which were, in fact, comparable to 
the control levels in sham control group.
ERCs suppressed the percentage of total macrophages, 
but increased M2 macrophages in the kidneys 
with attenuated IRI
To determine whether the macrophage profile was asso-
ciated with ERC-mediated attenuation of IRI, we meas-
ured total macrophage stained by anti-F4/80 mAb, and 
M2 macrophages stained by anti-F4/80 and CD206 mAbs 
Fig. 3 Infused ERCs suppress inflammatory cell infiltration in kidneys in response to IRI. The neutrophil and T cell accumulations in the kidney were 
examined using anti-Ly6G and anti-CD3 staining respectively 48 h after reperfusion following 30 min-ischemia injury. Representative sections of 
kidneys were obtained from sham control, IRI-untreated, and ERC-treated IRI mice. Magnification 100×
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by flow cytometry. We found that ERCs effectively sup-
pressed the percentage of total macrophages compared 
with those of untreated IRI group (p < 0.05), even though 
slightly higher than those of mice in sham control group 
(p < 0.05) (Fig. 6a). Interestingly, M2 macrophage popu-
lation was significantly increased in ERC-treated mice 
compared to that of untreated IRI mice (p < 0.05). In fact, 
the percentage of M2 macrophages was undistinguisha-
ble between mice in sham control group and ERC-treated 
IRI group (Fig. 6b).
ERCs attenuated kidney IRI by regulating cytokine 
expression
The serum levels of pro-inflammatory and anti-inflam-
matory cytokines were analyzed and compared among 
different groups. As shown in Fig. 7, the serum levels of 
pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) 
were markedly increased in untreated IRI group, whereas 
ERC treatment significantly reduced the pro-inflamma-
tory cytokine levels in the sera (p  <  0.05, ERC-treated 
group vs. untreated group), even though slightly higher 
Fig. 4 Infused ERCs increase the percentage of CD4+CD25+ Tregs in the spleen and contribute to the protection of kidney against IRI. a Flow 
cytometric analysis of splenic CD4+CD25+ Treg population was performed in the sham, IRI-untreated and ERC-treated groups. b ERC treatment 
significantly increased the percentage of Tregs in IRI mice compared with those of untreated IRI mice. Bar graphs represent mean ± SD of three 
separate experiments. p values were determined by one-way ANOVA. Data shown are a representative of three separate experiments performed 
(*p < 0.05, vs. IRI-untreated group, #p < 0.05, vs. sham group, n = 6)
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than the baseline serum levels in sham control group 
(p  <  0.05). Meanwhile, treatment with ERCs increased 
the level of the anti-inflammatory cytokine IL-4 in the 
sera (p < 0.05), which was even higher than that in sham 
control mice (p  <  0.05). These data suggest that ERCs 
not only suppress the expression of pro-inflammatory 
Fig. 5 ERCs suppress CD4+ and CD8+ T cell populations in the spleen and kidney. Flow cytometric analysis of CD4+ and CD8+ T cell populations 
was performed in the a spleen and b kidney of the sham, IRI-untreated and ERC-treated groups. c Treatment with ERCs significantly decreased the 
percentages of CD4+ and CD8+ T cells in the spleen and kidney. Bar graphs represent mean ± SD of three separate experiments. p values were 
determined by one-way ANOVA. Data shown are a representative of three separate experiments performed (*p < 0.01, vs. IRI-untreated group, 
n = 6)
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Fig. 6 ERCs decrease the percentage of total macrophages but increase M2 macrophages in the kidneys with IRI. Flow cytometric analysis of a 
F4/80+ total macrophages and b CD206+ M2 macrophages was performed in the kidneys of different groups. In Fig. 6a, vertical axis: FSC-H, hori-
zontal axis: F4/80. Bar graphs represent mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are a 
representative of three separate experiments performed (*p < 0.05, vs. IRI-untreated group, #p < 0.05, vs. sham group, n = 6)
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cytokines, but also enhance the level of anti-inflamma-
tory cytokines.
Discussion
As we all know, cell therapy has been reported to be an 
effective method in the treatment of some diseases. ERCs 
are an attractive novel type of adult MSCs, which can be 
obtained from menstrual blood. In the current study, we 
focused on their anti-inflammatory and immunomodula-
tory properties in attenuation of renal IRI. So we intra-
venously injected ERCs into mice suffering from renal 
IRI, an experimental model of ischemic AKI. We have 
highlighted several findings in this study. First, intra-
venously injected ERCs decreased intra-renal CD3+ T 
cell and neutrophil infiltration; second, ERCs increased 
the percentage of splenic Tregs in mice with attenuated 
renal damage; third, ERCs decreased CD4+ and CD8+ T 
cell population in both spleen and kidney; fourth, ERCs 
down-regulated the percentage of total macrophages, 
but increased M2 macrophages; finally, injected ERCs 
suppressed pro-inflammatory cytokines and enhanced 
anti-inflammatory cytokine expression in mice with 
Fig. 7 ERCs attenuate renal IRI by regulating cytokine levels. Serum samples were collected from the sham, IRI-untreated and ERC-treated groups. 
Serum levels of TNF-α, IFN-γ, IL-6 and IL-4 were examined by ELISA. Bar graphs represent mean ± SD of three separate experiments. p values were 
determined by one-way ANOVA. Data shown are a representative of three separate experiments performed (*p < 0.05, vs. IRI-untreated group, 
#p < 0.05, vs. sham group, n = 6)
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ameliorated renal function. To exclude if the therapeu-
tic potential of ERCs is only mediated by cellular com-
ponent, peripheral blood monocytes were also used as 
the cell treatment control. As expected, no therapeutic 
effects were observed according to the assessment of 
renal function and pathological study (data not shown).
ERCs, an attractive novel type of adult MSCs isolated 
from menstrual blood, were capable of differentiating 
into 9 lineages [22]. As we all know, MSCs are a group of 
self-renewing, pluripotent stromal cells derived from tis-
sues such as bone marrow [31], cord blood [32], adipose 
tissue [33] and amniotic fluid [34], and have been demon-
strated that they could promote tissue repair and possess 
immunomodulatory and anti-inflammatory properties. 
ERCs express CD9, CD13, CD14, CD29, CD44, CD73, 
CD90, CD105, CD117, CD133, CD146 [35], but not 
STRO-1, CD31 (endothelial) and CD34 (haemopoietic 
stem cell and endothelial) [36]. The human endometrium 
has unique immunological requirements in nature. For 
example, in pregnancy, the endometrium must toler-
ate invading embryo, which expresses both paternal and 
maternal antigens. A study demonstrated that endome-
trial MSCs were able to suppress neural inflammation 
in a mouse model of multiple sclerosis [37]. MSCs have 
been demonstrated to inhibit ongoing mixed lympho-
cyte reaction (MLR) [38], induce generation of regula-
tory T cells [39], and in vivo suppress autoimmunity such 
as collagen induced arthritis [40]. But the application 
of these cell types is limited by availability, invasiveness 
of extraction and in some cases by proliferative capac-
ity [22]. ERCs are a new type of MSCs, which have some 
advantages compared with many conventional sources of 
MSCs. ERCs can be easily expanded and used for females 
as a non-invasively obtained and ethically appropri-
ate autologous stem cell alternative [22]. We previously 
reported the role of ERCs in limb ischemia injury [21], 
UC [23] and recently in prevention of transplant rejec-
tion (unpublished data). However the role of ERCs in 
attenuation of IRI in kidney has not been tested.
The underlying mechanisms of renal IRI are complex, 
including activation and progression of the immune 
response [41]. Tregs play a critical role in suppression 
of both innate and adaptive immune responses [30]. 
CD4+CD25+ Tregs account for 5–10  % of the CD4+ 
T cell panel in healthy human and mice, which are suf-
ficient to play an important role in the maintenance of 
immune homeostasis and the limitation of autoimmune 
disease [42]. In several studies, the investigators used 
PC61, an anti-CD25 monoclonal antibody to deplete 
Tregs before renal ischemia to confirm the protective 
effect of the Tregs; depletion of Tregs leads to deteriora-
tion of the renal IRI compared to those of mice that only 
suffered from renal IRI and had no other treatment [28, 
43, 44]. In another study, the researchers used depletion 
and adoptive transfer strategy to determine the func-
tion of Tregs in the renal IRI model. Administration of 
anti-CD25 mAb significantly decreased the number of 
splenic Tregs [28, 45]. In addition, they observed that 
the adoptive transfer of Tregs back into Treg-depleted 
mice partially restored the protective effect of ischemic 
preconditioning [46–48]. Finally, partial depletion and 
adoptive transfer of Tregs partially mitigated or restored 
the renal injury [43, 49]. Blocking Tregs worsens AKI and 
infusion of Tregs protects organs against AKI induced by 
IRI [46, 50] and cisplatin [51], respectively. Collectively, 
these data suggested that Treg induction was one of the 
underlying mechanisms against renal IRI. In current 
study, we did not find statistically significant difference in 
the percentage of Tregs between sham control group and 
untreated IRI group, but observed that Tregs were sig-
nificantly increased by ERC treatment, even higher than 
that of sham control group. Thus, it indicated that ERC 
could increase Tregs which may be related to the sup-
pression of immune response and inflammatory reaction. 
As a result, intravenous injection of ERCs attenuated 
renal damage induced by IRI.
To investigate the effects of ERCs on different T lym-
phocyte subsets, we have also measured the levels of 
CD4+ and CD8+ T cells in different groups. Some stud-
ies have reported the effects of CD4+ and CD8+ T cells 
in renal IRI. In renal IRI, CD4 and CD8 double knock-
out mice demonstrated significant functional protection 
[52]. A more direct proof of the role of T cells in IRI has 
been demonstrated in a mouse liver injury model that a 
marked protection of liver function was found in T cell-
deficient athymic mice [53]. T cell-deficient mice could 
attenuate renal IRI, and T cell adoptive transfer into 
these mice restored the injury. Again CD4 knockout mice 
showed marked protection from renal IRI compared 
with wild-type mice and adoptive transfer of wild-type 
CD4+ cells into these CD4 knockout mice resulted in a 
worsening injury [9]. In current study, as compared with 
untreated IRI group, CD4+ and CD8+ T cells were sig-
nificantly reduced after ERC treatment, indicating that 
ERCs may reduce T cell accumulation. The results sug-
gested that ERCs may have regulatory functions on the 
cell populations of splenic CD4+ and CD8+ T cells. All 
the studies have demonstrated the critical role of CD4+ 
and CD8+ T cells in renal IRI.
Macrophages, belonging to the mononuclear phago-
cyte system, are potent immune regulators which play 
an important role in tissue homeostasis and remodeling 
[4, 54–56]. It has been reported that ablation of mac-
rophages by some different strategies 48–72  h after IRI 
could inhibit tubular repair and enhance injury [57–59]. 
In another study, adoptive transfer of resting RAW 264.7 
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macrophages (a mouse leukemic monocyte cell line) 
in macrophage-depleted mice after IRI could attenuate 
ischemic AKI and promote kidney repair [53, 60]. Mean-
while, macrophage-cell-based therapy can limit tubular 
injury and promote renal repair [61]. Accordingly, mac-
rophages show different functions and phenotypes in 
response to local metabolic and immune microenviron-
ment [62]. In general, there are two broad but distinct 
subsets of macrophages that are categorized as either clas-
sically activated (M1) or alternatively activated (M2) [63, 
64]. Recent studies have demonstrated that macrophages 
are key cells in both the initiation and resolution of renal 
injury [65–67]. In current study, ERC treatment induced 
the subset of M2 cells, which may play an important role 
in attenuation of renal IRI. This is consistent with previous 
finding that protection of the kidney against ischemia–
reperfusion injury and suppression of inflammation could 
be mediated by inducing M2 polarization [66], as well as 
the HO-1 expression promotes a “regulatory” M2 phe-
notype with the large augmentation in IL-10 production 
[68]. Several studies also have found that the different 
macrophage subset populations can be recruited and/or 
activated during different phases of ischemic injury and 
repair [56, 59, 69]. However, the mechanism of phenotype 
switching from pro-inflammatory to anti-inflammatory 
state is not fully understood in damaged kidney caused by 
IRI. Further studies to dissect these issues are warranted.
In this study, we have also assessed renal inflamma-
tory cytokines 48 h after renal IRI. It is well known that 
inflammation is induced by IRI, typically occurs in the 
absence of microorganisms, and has been termed as ster-
ile inflammation [70]. Similar to the response to invad-
ing pathogens, the sterile inflammation induced by IRI 
can also lead to the marked recruitment of neutrophils 
and the production of cytokines [70]. Neutrophils and 
macrophages were the initial infiltrates in the injury 
phase of renal IRI. Similarly, based on our data, IRI also 
increased the influx of macrophages and neutrophils, but 
ERCs reduced the influx of those cells during the post-
ischemic period. On the other hand, cytokines may play 
important roles in IRI. Although there is extensive litera-
ture regarding the function of cytokines in post-ischemic 
tissue injury, we only focused on TNF-α, IFN-γ, IL-6 and 
IL-4 in this study. As assessed by ELISA, the pro-inflam-
matory cytokines, such as TNF-α, IFN-γ and IL-6, were 
obviously higher in the untreated IRI group than those 
of sham group. Once released, they bind with specific 
receptors to induce the expression of chemokines. These 
activities promote the recruitment and activation of neu-
trophils in post-ischemic tissues. Finally, they affected the 
outcome of the renal IRI.
Concerning the source of ERCs, it has been found that 
endometrial MSCs’ perivascular location in both the 
basal and functional layers, indicating that they will be 
shed each month during menstruation [71]. To date, the 
source of endometrial MSCs is not yet clear. It is claimed 
that endometrial MSCs originate from resident stem/
progenitor cells. A further study of the specific charac-
terization of ERCs and the mechanisms of ERC-mediated 
protection in IRI is still underway.
Conclusions
Our data suggest that ERC treatment is able to protect 
kidneys against IRI, by significantly decreasing histologi-
cal damage,inflammatory infiltration, pro-inflammatory 
cytokine expression, as well as up-regulating Tregs, M2 
macrophages and anti-inflammatory cytokines. There-
fore, ERCs might provide a novel and potent therapeu-
tic option to prevent renal IRI. The clinical availability of 
ERCs might further facilitate rapid clinical translation of 
the present findings in this study.
Abbreviations
ERC: endometrial regenerative cells; IRI: ischemia–reperfusion injury; Treg: 
regulatory T cell; MSC: mesenchymal stem cells; TNF: tumor necrosis factor; IL: 
interleukin.
Authors’ contributions
PS, JL and WWL carried out the research, analyzed the data and drafted the 
manuscript. XX, HL, and HH analyzed the data. CD participated in the design 
of the study and revised the manuscript. HW conceived of the study, partici-
pated in its design and coordination, and revised the manuscript. All authors 
read and approved the final manuscript.
Author details
1 Department of General Surgery, Tianjin Medical University General Hospital, 
154 Anshan Road, Heping District, Tianjin 300052, China. 2 Tianjin General Sur-
gery Institute, Tianjin, China. 3 Department of Gastroenterology and Hepatol-
ogy, Tianjin Medical University General Hospital, Tianjin, China. 4 Department 
of Gynecology and Obstetrics, Tianjin Medical University General Hospital, 
Tianjin, China. 5 Department of Urologic Sciences, The University of British 
Columbia, Vancouver, BC, Canada. 6 Immunity and Infection Research Centre, 
Vancouver Coastal Health Research Institute, Vancouver, BC, Canada. 
Acknowledgements
This work was supported by grants to H.W. from National Natural Science 
Foundation of China (No. 81273257 and 81471584), Tianjin Application Basis 
and Cutting-Edge Technology Research Grant (14JCZDJC35700), and Li 
Jieshou Intestinal Barrier Research Special Fund (LJS-201412). The authors are 
grateful to Dr. Tao Shi for his technical support and review of pathological 
slides.
Competing interests
All authors declare that they have no competing interests.
Received: 17 October 2015   Accepted: 13 January 2016
References
 1. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, 
Cosio FG. Identifying specific causes of kidney allograft loss. Am J Trans-
plant. 2009;9:527–35.
 2. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory dis-
ease? Kidney Int. 2004;66:480–5.
Page 12 of 13Sun et al. J Transl Med  (2016) 14:28 
 3. Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron 
Exp Nephrol. 2008;109:e102–7.
 4. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the 
initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant. 
2006;21:1231–9.
 5. Ranganathan PV, Jayakumar C, Mohamed R, Dong Z, Ramesh G. Netrin-1 
regulates the inflammatory response of neutrophils and macrophages, 
and suppresses ischemic acute kidney injury by inhibiting COX-2-medi-
ated PGE2 production. Kidney Int. 2013;83:1087–98.
 6. Jones DR, Lee HT. Protecting the kidney during critical illness. Curr Opin 
Anaesthesiol. 2007;20:106–12.
 7. Miura M, Fu X, Zhang QW, Remick DG, Fairchild RL. Neutralization of 
Gro alpha and macrophage inflammatory protein-2 attenuates renal 
ischemia/reperfusion injury. Am J Pathol. 2001;159:2137–45.
 8. Day YJ, Huang L, Ye H, Linden J, Okusa MD. Renal ischemia-reperfusion 
injury and adenosine 2A receptor-mediated tissue protection: role of 
macrophages. Am J Physiol Renal Physiol. 2005;288:F722–31.
 9. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O’Donnell MP, 
Rabb H. Identification of the CD4(+) T cell as a major pathogenic factor in 
ischemic acute renal failure. J Clin Invest. 2001;108:1283–90.
 10. Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strieter RM, Rosin DL, 
Okusa MD. IL-17 produced by neutrophils regulates IFN-gamma-medi-
ated neutrophil migration in mouse kidney ischemia-reperfusion injury. J 
Clin Invest. 2010;120:331–42.
 11. Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reper-
fusion injury. Semin Nephrol. 2010;30:268–77.
 12. Jang HR, Rabb H. The innate immune response in ischemic acute kidney 
injury. Clin Immunol. 2009;130:41–50.
 13. Ferenbach DA, Sheldrake TA, Dhaliwal K, Kipari TM, Marson LP, Kluth DC, 
Hughes J. Macrophage/monocyte depletion by clodronate, but not diph-
theria toxin, improves renal ischemia/reperfusion injury in mice. Kidney 
Int. 2012;82:928–33.
 14. Lai LW, Yong KC, Igarashi S, Lien YH. A sphingosine-1-phosphate type 
1 receptor agonist inhibits the early T-cell transient following renal 
ischemia-reperfusion injury. Kidney Int. 2007;71:1223–31.
 15. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance 
wound healing through differentiation and angiogenesis. Stem Cells. 
2007;25:2648–59.
 16. Imanishi Y, Saito A, Komoda H, Kitagawa-Sakakida S, Miyagawa S, Kondoh 
H, Ichikawa H, Sawa Y. Allogenic mesenchymal stem cell transplantation 
has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell 
Cardiol. 2008;44:662–71.
 17. de Vries DK, Schaapherder AF, Reinders ME. Mesenchymal stromal cells in 
renal ischemia/reperfusion injury. Front Immunol. 2012;3:162.
 18. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller 
MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of 
mesenchymal stem cells: advances and applications. Curr Mol Med. 
2012;12:574–91.
 19. He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-
derived mesenchymal stem cells for treatment of experimental colitis in 
mice. Dig Dis Sci. 2012;57:3136–44.
 20. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory prop-
erties of mesenchymal stem cells: cytokines and factors. Am J Reprod 
Immunol. 2012;67:1–8.
 21. Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau 
AM, Pyszniak A, Carrier E, Ichim TE, Riordan NH. Allogeneic endometrial 
regenerative cells: an “Off the shelf solution” for critical limb ischemia? J 
Transl Med. 2008;6:45.
 22. Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, Wang H, Ge W, 
Bogin V, Chan KW, Thebaud B, Riordan NH. Endometrial regenerative cells: 
a novel stem cell population. J Transl Med. 2007;5:57.
 23. Lv Y, Xu X, Zhang B, Zhou G, Li H, Du C, Han H, Wang H. Endometrial 
regenerative cells as a novel cell therapy attenuate experimental colitis in 
mice. J Transl Med. 2014;12:344.
 24. Borlongan CV, Kaneko Y, Maki M, Yu SJ, Ali M, Allickson JG, Sanberg CD, 
Kuzmin-Nichols N, Sanberg PR. Menstrual blood cells display stem cell-
like phenotypic markers and exert neuroprotection following transplan-
tation in experimental stroke. Stem Cells Dev. 2010;19:439–52.
 25. Drago H, Marin GH, Sturla F, Roque G, Martire K, Diaz Aquino V, Lamonega 
R, Gardiner C, Ichim T, Riordan N, Raimondi JC, Bossi S, Samadikuchak-
saraei A, van Leeuwen M, Tau JM, Nunez L, Larsen G, Spretz R, Mansilla 
E. The next generation of burns treatment: intelligent films and matrix, 
controlled enzymatic debridement, and adult stem cells. Transplant Proc. 
2010;42:345–9.
 26. Hida N, Nishiyama N, Miyoshi S, Kira S, Segawa K, Uyama T, Mori 
T, Miyado K, Ikegami Y, Cui C, Kiyono T, Kyo S, Shimizu T, Okano T, 
Sakamoto M, Ogawa S, Umezawa A. Novel cardiac precursor-like cells 
from human menstrual blood-derived mesenchymal cells. Stem Cells. 
2008;26:1695–704.
 27. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Shar-
land AF, Chadban SJ. TLR4 activation mediates kidney ischemia/reperfu-
sion injury. J Clin Invest. 2007;117:2847–59.
 28. Hu J, Zhang L, Wang N, Ding R, Cui S, Zhu F, Xie Y, Sun X, Wu D, Hong Q, Li 
Q, Shi S, Liu X, Chen X. Mesenchymal stem cells attenuate ischemic acute 
kidney injury by inducing regulatory T cells through splenocyte interac-
tions. Kidney Int. 2013;84:521–31.
 29. Wang W, Faubel S, Ljubanovic D, Mitra A, Falk SA, Kim J, Tao Y, Soloviev A, 
Reznikov LL, Dinarello CA, Schrier RW, Edelstein CL. Endotoxemic acute 
renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal 
Physiol. 2005;288:F997–1004.
 30. Lee VW, Wang YM, Wang YP, Zheng D, Polhill T, Cao Q, Wu H, Alexander IE, 
Alexander SI, Harris DC. Regulatory immune cells in kidney disease. Am J 
Physiol Renal Physiol. 2008;295:F335–42.
 31. Edwards RG. Stem cells today: B1. Bone marrow stem cells. Reprod 
Biomed Online. 2004;9:541–83.
 32. Harris DT, Badowski M, Ahmad N, Gaballa MA. The potential of cord 
blood stem cells for use in regenerative medicine. Expert Opin Biol Ther. 
2007;7:1311–22.
 33. Parker AM, Katz AJ. Adipose-derived stem cells for the regeneration of 
damaged tissues. Expert Opin Biol Ther. 2006;6:567–78.
 34. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mosto-
slavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A. Isolation 
of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 
2007;25:100–6.
 35. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause 
D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining 
multipotent mesenchymal stromal cells. The International Society for 
Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
 36. Dimitrov R, Timeva T, Kyurkchiev D, Stamenova M, Shterev A, Kostova P, 
Zlatkov V, Kehayov I, Kyurkchiev S. Characterization of clonogenic stromal 
cells isolated from human endometrium. Reproduction. 2008;135:551–8.
 37. Peron JP, Jazedje T, Brandao WN, Perin PM, Maluf M, Evangelista LP, Halp-
ern S, Nisenbaum MG, Czeresnia CE, Zatz M, Camara NO, Rizzo LV. Human 
endometrial-derived mesenchymal stem cells suppress inflammation in 
the central nervous system of EAE mice. Stem Cell Rev. 2012;8:940–52.
 38. Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Zhao RC. 
Allogeneic bone marrow-derived flk-1 + Sca-1- mesenchymal stem 
cells leads to stable mixed chimerism and donor-specific tolerance. Exp 
Hematol. 2004;32:861–7.
 39. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of 
CD4 + or CD8 + regulatory T cells upon mesenchymal stem cell-lym-
phocyte interaction. Haematologica. 2007;92:881–8.
 40. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using 
allogeneic bone marrow mesenchymal stem cells prevents tissue dam-
age in collagen-induced arthritis. Arthritis Rheum. 2007;56:1175–86.
 41. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. 
Nat Rev Immunol. 2010;10:826–37.
 42. Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell 
therapy for inflammatory bowel disease: more questions than answers. 
Immunology. 2012;136:115–22.
 43. Lai LW, Yong KC, Lien YH. Pharmacologic recruitment of regula-
tory T cells as a therapy for ischemic acute kidney injury. Kidney Int. 
2012;81:983–92.
 44. Rabb H, Ramirez G, Saba SR, Reynolds D, Xu J, Flavell R, Antonia S. Renal 
ischemic-reperfusion injury in L-selectin-deficient mice. Am J Physiol. 
1996;271:F408–13.
 45. Jun C, Ke W, Qingshu L, Ping L, Jun D, Jie L, Bo C, Su M. Protective effect 
of CD4(+)CD25(high)CD127(low) regulatory T cells in renal ischemia-
reperfusion injury. Cell Immunol. 2014;289:106–11.
 46. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H, Ju ST, Okusa MD. 
Regulatory T cells suppress innate immunity in kidney ischemia-reperfu-
sion injury. J Am Soc Nephrol. 2009;20:1744–53.
Page 13 of 13Sun et al. J Transl Med  (2016) 14:28 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 47. Lee H, Nho D, Chung HS, Lee H, Shin MK, Kim SH, Bae H. CD4+CD25+ 
regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. 
Kidney Int. 2010;78:1100–9.
 48. Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, Lobo PI, 
Okusa MD. Autocrine adenosine signaling promotes regulatory T cell-
mediated renal protection. J Am Soc Nephrol. 2012;23:1528–37.
 49. Cho WY, Choi HM, Lee SY, Kim MG, Kim HK, Jo SK. The role of Tregs and 
CD11c(+) macrophages/dendritic cells in ischemic preconditioning of 
the kidney. Kidney Int. 2010;78:981–92.
 50. Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD. Regulatory T cells contrib-
ute to the protective effect of ischemic preconditioning in the kidney. 
Kidney Int. 2010;77:771–80.
 51. Yoshida T, Kurella M, Beato F, Min H, Ingelfinger JR, Stears RL, Swinford 
RD, Gullans SR, Tang SS. Monitoring changes in gene expression in renal 
ischemia-reperfusion in the rat. Kidney Int. 2002;61:1646–54.
 52. Rabb H, Daniels F, O’Donnell M, Haq M, Saba SR, Keane W, Tang WW. 
Pathophysiological role of T lymphocytes in renal ischemia-reperfusion 
injury in mice. Am J Physiol Renal Physiol. 2000;279:F525–31.
 53. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, Engelhardt JF. 
CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflamma-
tory responses in mouse liver. J Clin Invest. 1997;100:279–89.
 54. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the 
development of renal fibrosis following ischaemia/reperfusion-induced 
acute kidney injury. Nephrol Dial Transplant. 2008;23:842–52.
 55. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, 
homeostasis and disease. Nature. 2013;496:445–55.
 56. Filardy AA, Pires DR, Nunes MP, Takiya CM, Freire-de-Lima CG, Ribeiro-
Gomes FL, DosReis GA. Proinflammatory clearance of apoptotic 
neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in 
macrophages. J Immunol. 2010;185:2044–50.
 57. Jang HS, Kim J, Park YK, Park KM. Infiltrated macrophages contribute to 
recovery after ischemic injury but not to ischemic preconditioning in 
kidneys. Transplantation. 2008;85:447–55.
 58. Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT, Pei H, Chen L, Zheng JJ, 
Carroll TJ, Pollard JW, McMahon AP, Lang RA, Duffield JS. Macrophage 
Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci 
USA. 2010;107:4194–9.
 59. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C, Cantley LG. 
Distinct macrophage phenotypes contribute to kidney injury and repair. J 
Am Soc Nephrol. 2011;22:317–26.
 60. Jung M, Sola A, Hughes J, Kluth DC, Vinuesa E, Vinas JL, Perez-Ladaga A, 
Hotter G. Infusion of IL-10-expressing cells protects against renal ischemia 
through induction of lipocalin-2. Kidney Int. 2012;81:969–82.
 61. Vinuesa E, Hotter G, Jung M, Herrero-Fresneda I, Torras J, Sola A. Mac-
rophage involvement in the kidney repair phase after ischaemia/reperfu-
sion injury. J Pathol. 2008;214:104–13.
 62. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev 
Immunol. 2005;5:953–64.
 63. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 
2003;3:23–35.
 64. Wang Y, Harris DC. Macrophages in renal disease. J Am Soc Nephrol. 
2011;22:21–7.
 65. Kluth DC, Erwig LP, Rees AJ. Multiple facets of macrophages in renal 
injury. Kidney Int. 2004;66:542–57.
 66. Ranganathan PV, Jayakumar C, Ramesh G. Netrin-1-treated macrophages 
protect the kidney against ischemia-reperfusion injury and suppress 
inflammation by inducing M2 polarization. Am J Physiol Renal Physiol. 
2013;304:F948–57.
 67. Huen SC, Cantley LG. Macrophage-mediated injury and repair after 
ischemic kidney injury. Pediatr Nephrol. 2015;30:199–209.
 68. Ferenbach DA, Ramdas V, Spencer N, Marson L, Anegon I, Hughes J, Kluth 
DC. Macrophages expressing heme oxygenase-1 improve renal function 
in ischemia/reperfusion injury. Mol Ther. 2010;18:1706–13.
 69. Alikhan MA, Jones CV, Williams TM, Beckhouse AG, Fletcher AL, Kett 
MM, Sakkal S, Samuel CS, Ramsay RG, Deane JA, Wells CA, Little MH, 
Hume DA, Ricardo SD. Colony-stimulating factor-1 promotes kidney 
growth and repair via alteration of macrophage responses. Am J Pathol. 
2011;179:1243–56.
 70. Kvietys PR, Granger DN. Role of reactive oxygen and nitrogen spe-
cies in the vascular responses to inflammation. Free Radic Biol Med. 
2012;52:556–92.
 71. Ulrich D, Muralitharan R, Gargett CE. Toward the use of endometrial and 
menstrual blood mesenchymal stem cells for cell-based therapies. Expert 
Opin Biol Ther. 2013;13:1387–400.
